FTSE 100 news / Companies and sectors / Pharma and healthcare / 19 October 2026
Pharma and healthcare: sector news on Monday 19 October 2026
Average tone +3.3 (positive) across 4 companies with relevant coverage, from 17 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| GSK | +8.5 | 7 | Coverage was mainly about positive early-stage lung cancer data for Ris-Rez, with a 61% response rate reported. |
| Haleon | +7.0 | 5 | Coverage focused on Haleon's results helped by Sensodyne and oral health strength, ahead of a Q3 update. |
| AstraZeneca | +4.0 | 3 | Coverage was light, centred on a preview of AstraZeneca's investor event and news that its asthma, RSV and cancer drugs received PBAC approval. |
| Smith & Nephew | −6.3 | 2 | Coverage was led by Smith & Nephew cutting its sales outlook, which weighs on the tone. |
| Convatec | – | 0 |
Strongest stories in the sector
- +10.0 GSK lung cancer drug shows 61% response rate in early global trial
Strong 61% response rate in early lung cancer trial. - −10.0 Blue-Chip Stock Smith & Nephew (LSE:SN.) Cuts Sales Outlook: What It Means
Company cut its sales outlook, a clear negative for prospects. - +9.7 GSK Reports 61% Overall Response Rate For Ris-Rez In Phase IB Trial
Reports 61% overall response rate in Phase IB trial. - +9.2 REG - GSK PLC - Ris-Rez positive early data in lung cancer
Company announcement of positive early lung cancer data. - +9.2 Blue-Chip Stock Haleon (LSE:HLN) Results Powered By Sensodyne: What It Means
Results driven by Sensodyne strength, framed positively. - +8.7 FTSE 100 Haleon (LSE:HLN): Oral Health Strength Lifts Profit Ahead of Q3 Update
Oral health strength lifts profit ahead of Q3 update. - +8.0 Blue-Chip Stock GSK (LSE:GSK) Beats Forecasts And Launches Efficiency Drive: What It Means
Results beat forecasts and efficiency drive launched. - +7.5 Goldman Sachs keeps Buy rating for Haleon stock at GBp 460.00 - ad-hoc-news.de
Goldman Sachs maintains Buy rating with 460p target. - +6.3 Asthma, RSV and cancer drugs get PBAC nod
Asthma, RSV and cancer drugs reportedly recommended by Australian PBAC; positive for products. - +6.0 GSK (LSE:GSK) Stock Looks Undervalued On Its 59% Five Year Run
Valuation piece calls shares undervalued after strong five-year run. - +5.7 Smith & Nephew launches CARTIHEAL before Smith & Nephew stock results - ad-hoc-news.de
Product launch of CARTIHEAL is positive ahead of results. - +4.2 Will Headache Remedy Launch Change Haleon's (LSE:HLN) Narrative
Headache remedy launch could shift narrative; mildly positive, uncertain.
Pharma and healthcare: every day · FTSE 100 overview for the day